Answers are grounded in this paper and cite their sources.
Preclinical study demonstrates that m6A-modified SSTR5-AS1 inhibits ferroptosis in esophageal cancer cells by stabilizing UHRF1, highlighting a potential therapeutic target.
Long non-coding RNA SSTR5-AS1 is upregulated in esophageal cancer (EC) and correlates with poor prognosis. This study investigates its role in EC progression and its underlying mechanisms. In this study, SSTR5-AS1 is significantly overexpressed in EC tissues and cancer cell lines, correlating with poor prognosis. Functional assays reveal that SSTR5-AS1 enhances cell proliferation, colony formation, migration, and invasion. Knockdown of SSTR5-AS1 induces ferroptosis, evidenced by increased lipid ROS, Fe 2+ , and MDA levels, and decreased GSH levels. Ferroptosis inhibitors reverse these effects. SSTR5-AS1 stabilizes UHRF1 mRNA through interaction with FAM120A. Mechanistically, the stability of SSTR5-AS1 is maintained by IGF2BP1 and METTL3 in an m6A-dependent manner. In conclusion, SSTR5-AS1 promotes EC progression by inhibiting ferroptosis and stabilizing UHRF1 through the SSTR5-AS1 /FAM120A/UHRF1 axis. IGF2BP1 and METTL3 play crucial roles in regulating SSTR5-AS1 stability via m6A modification. These findings highlight SSTR5-AS1 as a potential therapeutic target and provide new insights into m6A-mediated regulation in cancer.
No takes yet. Share an insight, caveat, or question.
Zhang et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: